Metis Global Partners LLC Sells 74 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Metis Global Partners LLC reduced its stake in United Therapeutics Co. (NASDAQ:UTHR) by 4.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,430 shares of the biotechnology company’s stock after selling 74 shares during the period. Metis Global Partners LLC’s holdings in United Therapeutics were worth $505,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in UTHR. Newbridge Financial Services Group Inc. bought a new position in shares of United Therapeutics during the fourth quarter valued at approximately $25,000. Brooklyn Investment Group purchased a new stake in United Therapeutics during the third quarter valued at approximately $33,000. Capital Performance Advisors LLP purchased a new position in shares of United Therapeutics in the third quarter worth $82,000. MassMutual Private Wealth & Trust FSB raised its holdings in shares of United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after buying an additional 58 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in shares of United Therapeutics by 673.9% in the third quarter. Farther Finance Advisors LLC now owns 356 shares of the biotechnology company’s stock worth $128,000 after buying an additional 310 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Trading Up 0.8 %

UTHR opened at $310.98 on Thursday. The firm has a market capitalization of $13.97 billion, a PE ratio of 13.66, a PEG ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a twelve month low of $221.53 and a twelve month high of $417.82. The firm’s 50-day moving average price is $357.53 and its 200 day moving average price is $360.79.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period in the previous year, the business posted $4.36 earnings per share. As a group, analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now directly owns 5,528 shares of the company’s stock, valued at $1,966,696.56. The trade was a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $929,678.52. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 116,464 shares of company stock worth $42,396,244. 11.90% of the stock is owned by insiders.

Analysts Set New Price Targets

UTHR has been the topic of several analyst reports. UBS Group raised their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.